Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

Glaucoma Research Foundation (GRF) announced the nine recipients of its $55,000 one-year Shaffer Research Grants. "We are extremely fortunate for the ongoing and generous investment from our glaucoma ...

EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

Cystic fibrosis (CF) is a life-threatening autosomal recessive disease affecting over 160,000 people worldwide. CF is caused by loss-of-function mutations in the CF transmembrane conductance regulator ...

Here, authors succeed in enlarging the noncatalytic REC domain of Streptococcus pyogenes Cas9 and harnessing this giant SpCas9 (GS-Cas9) scaffold to improve the precision of base editing.

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $80 price target on Beam Therapeutics (BEAM) shares after the company ...

He's term limited as governor after 2026. So why not start a pod and start having guests who might attract an audience outside your own political base. And certainly, Charlie Kirk, at age 31, with ...

Chase Fralick got it.” Leading 7-4 with two outs and the bases loaded in the seventh inning, Fralick hit a backside double to clear the bases and push Auburn’s lead to six. The game marked ...

Despite demonstrating feasibility for mitochondrial adenine base editing, the study highlights significant limitations, underscoring the need for further optimization. The reviewer also suggests ...

The authors have demonstrated the use of adenine base editors delivered via adeno-associated viruses to introduce edits in the mitochondrial genome. The manuscript describes the methodology well, and ...

Zhan et al. (2019) have skillfully designed and fabricated a thermal-triggered PS release system adopting DNA complementary base pairs. In their work, adenine (A) was firstly modified on the surface ...